A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

@article{Furie2011API,
  title={A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.},
  author={Richard A. Furie and Michelle A. Petri and Omid Zamani and Ricard Cervera and Daniel J Wallace and Dana Tegzov{\'a} and Jorge S{\'a}nchez-Guerrero and Andreas Schwarting and Joan T. Merrill and W. Winn Chatham and William Stohl and Ellen M Ginzler and Douglas R. Hough and Z. John Zhong and William W. Freimuth and Ronald F. van Vollenhoven},
  journal={Arthritis and rheumatism},
  year={2011},
  volume={63 12},
  pages={
          3918-30
        }
}
OBJECTIVE To assess the efficacy/safety of the B lymphocyte stimulator inhibitor belimumab plus standard therapy compared with placebo plus standard therapy in active systemic lupus erythematosus (SLE). METHODS In a phase III, multicenter, randomized, placebo-controlled trial, 819 antinuclear antibody-positive or anti-double-stranded DNA-positive SLE patients with scores ≥6 on the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) version of the SLE Disease Activity Index… 

Figures and Tables from this paper

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study
TLDR
This study successfully identified a safe, effective and convenient dose, study population and end point for evaluation of blisibimod effect in Phase 3 of patients with systemic lupus erythematosus.
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
TLDR
Patients treated with tabalumab had greater SRI-5 response rates in a serologically active subset and improvements in more stringent SRI cut-offs, SELENA-SLEDAI, Physician's Global Assessment, anti-double-stranded DNA antibodies, complement, total B cells and immunoglobulins.
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial
TLDR
Although the SRI-6 end point was not met, blisibimod was associated with successful steroid reduction, decreased proteinuria and biomarker responses, and was well-tolerated.
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
TLDR
Tabalumab had biological activity—changes in anti-dsDNA, complement, B cells and immunoglobulins—consistent with BAFF pathway inhibition; safety profiles were similar with tabalumab and placebo; key clinical efficacy endpoints did not achieve statistical significance.
A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea
TLDR
In patients with SLE from North East Asia, belimumab significantly improved disease activity, while reducing prednisone use, with no new safety issues.
Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol
TLDR
Belimumab and rituximab combination may be a highly effective treatment of SLE and this study aims to evaluate and compare the efficacy, safety and tolerability of subcutaneous (SC) belitationab and a single cycle of ritUXimab in patients with SLE with belimumab alone.
Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial
TLDR
In Japanese patients with SLE,Belimumab improved disease activity, with efficacy and safety results similar and consistent to the pivotal Phase 3 trials, suggesting that belimumab is a potential treatment option in this population.
Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial
TLDR
The efficacy of low-dose belimumab for prevention of disease flares in patients with SLE with low disease activity is explored and key findings will be presented at national and international conferences.
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial
TLDR
PF-04236921 was not significantly different from placebo for the primary efficacy end point in patients with SLE and evidence of an effect with 10 mg was seen in a post hoc analysis.
Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial
TLDR
Organ system improvements were seen in more Japanese belimumab-treated than placebo-treated patients, providing further evidence supportingBelimumab use in Japanese patients with SLE.
...
...

References

SHOWING 1-10 OF 45 REFERENCES
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
TLDR
Belimumab was biologically active and well tolerated and the effect of belimumab on the reduction of SLE disease activity or flares was not significant, however, serologically active SLE patients responded significantly better to belicumab therapy plus SOC than to SOC alone.
Novel evidence-based systemic lupus erythematosus responder index.
TLDR
This evidence-based evaluation of a large randomized, placebo-controlled trial in SLE resulted in the ability to define a robust responder index based on improvement in disease activity without worsening the overall condition or the development of significant disease activity in new organ systems.
Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.
TLDR
The data confirm the dependence of newly formed B cells on BLyS for survival in humans, and suggest that memory B cells and plasma cells are less susceptible to selective BLYS inhibition.
Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
TLDR
The results lend support to the notion that BLyS is a candidate for therapeutic targeting in SLE, and a relationship between circulatingBLyS levels and SLE disease activity is demonstrated.
Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects.
  • W. Halpern, P. Lappin, K. Baker
  • Biology, Medicine
    Toxicological sciences : an official journal of the Society of Toxicology
  • 2006
TLDR
Data confirm the specific pharmacologic activity of belimumab in reducing B lymphocytes in the cynomolgus monkey, and the favorable safety profile and lack of treatment-related infections also support continued clinical development ofBelimumab.
Damage in systemic lupus erythematosus and its association with corticosteroids.
TLDR
SLE patients receiving long-term prednisone therapy were at significant risk of morbidity due to permanent organ damage and new steroid-sparing therapies are needed in order to treat disease activity and minimize cumulative and high-doseprednisone exposure.
Combined oral contraceptives in women with systemic lupus erythematosus.
TLDR
This study indicates that oral contraceptives do not increase the risk of flare among women with systemic lupus erythematosus whose disease is stable and is within the prespecified 9 percent margin for noninferiority.
Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus.
TLDR
Flow cytometric monitoring of B cell subsets in the peripheral blood provides new insights into abnormalities of B Cell function in SLE and may also be a diagnostically valuable option for monitoring the activity of this autoimmune disease.
...
...